Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.

Published

Journal Article

BACKGROUND: Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction 20%), no benefit of ICD treatment was seen. Projected over each patient's predicted lifespan, ICD treatment added 6.3, 4.1, 3.0, 1.9, and 0.2 additional years of life in the lowest- to highest-risk groups, respectively. CONCLUSIONS: A clinical risk prediction model identified subsets of moderately symptomatic heart failure patients in SCD-HeFT in whom single-lead ICD therapy was of no benefit and other subsets in which benefit was substantial.

Full Text

Duke Authors

Cited Authors

  • Levy, WC; Lee, KL; Hellkamp, AS; Poole, JE; Mozaffarian, D; Linker, DT; Maggioni, AP; Anand, I; Poole-Wilson, PA; Fishbein, DP; Johnson, G; Anderson, J; Mark, DB; Bardy, GH

Published Date

  • September 8, 2009

Published In

Volume / Issue

  • 120 / 10

Start / End Page

  • 835 - 842

PubMed ID

  • 19704100

Pubmed Central ID

  • 19704100

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.108.816884

Language

  • eng

Conference Location

  • United States